Oneness Biotech Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Chih-Hui Cheng

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	2.4yrs
CEO ownership	0.4%
Management average tenure	no data
Board average tenure	7.4yrs

Recent management updates

Recent updates

Announcing: Oneness Biotech (GTSM:4743) Stock Soared An Exciting 936% In The Last Three Years

Mar 01

CEO Compensation Analysis

How has Chih-Hui Cheng's remuneration changed compared to Oneness Biotech's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	n/a	n/a	-NT$1b
Sep 30 2023	n/a	n/a	-NT$1b
Jun 30 2023	n/a	n/a	-NT$967m
Mar 31 2023	n/a	n/a	-NT$293m
Dec 31 2022	n/a	n/a	NT$360m
Sep 30 2022	n/a	n/a	NT$1b
Jun 30 2022	n/a	n/a	NT$679m
Mar 31 2022	n/a	n/a	-NT$132m
Dec 31 2021	NT$3m	NT$1m	-NT$403m
Sep 30 2021	n/a	n/a	-NT$1b
Jun 30 2021	n/a	n/a	-NT$901m
Mar 31 2021	n/a	n/a	NT$64m
Dec 31 2020	NT$5m	NT$1m	-NT$242m

Compensation vs Market: Insufficient data to establish whether Chih-Hui's total compensation is reasonable compared to companies of similar size in the TW market.

Compensation vs Earnings: Chih-Hui's compensation has been consistent with company performance over the past year.

CEO

Chih-Hui Cheng

2.4yrs

Tenure

NT$2,769,000

Compensation

Ms. Chih-Hui Cheng serves as General Manager and Supervisor of Corporate Governance at Oneness Biotech Co., Ltd. since December 30, 2021. She served as Deputy General Manager of Finance Department at Onene...

Board Members

Name	Position	Tenure	Compensation	Ownership
Yi-Fu Lin	Director	2yrs	no data	no data
Shan-Ney Huang	Chairman	8.9yrs	NT$1.29m	no data
Suei Lu	Independent Director	5.9yrs	NT$289.00k	no data
Jui-Wen Huang	Independent Director	8.9yrs	NT$289.00k	no data
Hsien-Shou Kuo	Representative Director	14.1yrs	NT$22.00k	no data
Shih-Hua Hsu	Representative Director	11.9yrs	NT$22.00k	no data
San-Kuei Huang	Independent Director	2.8yrs	NT$181.00k	no data
Rey-Yuh Wu	Independent Director	2.8yrs	NT$126.00k	no data

7.4yrs

Average Tenure

Experienced Board: 4743's board of directors are considered experienced (7.4 years average tenure).

Oneness Biotech Management

Management criteria checks 2/4

Key information

Recent management updates

Oneness Biotech Co., Ltd., Annual General Meeting, May 21, 2024

Oneness Biotech Co., Ltd., Annual General Meeting, Apr 18, 2023

Oneness Biotech Co., Ltd. Announces the By-Election of Lin, Yi-Fu as Director

Oneness Biotech Co., Ltd. Announces the By-Election of Lin, Yi-Fu as Director

Oneness Biotech Co., Ltd., Annual General Meeting, May 24, 2022

Oneness Biotech Co., Ltd., Annual General Meeting, May 21, 2021

Recent updates

New minor risk - Shareholder dilution

Full year 2023 earnings: EPS and revenues miss analyst expectations

New major risk - Revenue and earnings growth

Oneness Biotech Co., Ltd. has filed a Follow-on Equity Offering.

Oneness Biotech Co., Ltd., Annual General Meeting, May 21, 2024

Oneness Biotech Co., Ltd. Announces Submission of A Phase II Clinical Trial Protocol Forsubcutaneous Injection Formulation of FB825 in Patientswith Moderate-To-Severe Atopic Dermatitis

Oneness Biotech Co., Ltd. Obtains Import License in Thailand from Thai Food and Drug Administration

Oneness Biotech Co., Ltd. Obtains Import License in Thailand from Thai Food and Drug Administration

Price target decreased by 14% to NT$262

Consensus revenue estimates increase by 158%

Oneness Biotech Co., Ltd. Announces Approval of FESPIXON

New minor risk - Share price stability

New minor risk - Shareholder dilution

Oneness Biotech Co., Ltd. Submits 510(k) Application to the U.S. FDA to Expand the Intended Patient Population and Add Multiple Chronic Wound Indications for Bonvadis

New minor risk - Revenue size

Second quarter 2023 earnings: EPS misses analyst expectations

New minor risk - Profitability

Price target decreased by 10% to NT$274

Oneness Biotech Co., Ltd. Announces Submission of Registration Application for Bonvadis, the Wound Care Topical Cream to the Drug Regulatory Authority of Pakistan (DRAP)

US FDA agrees to proceed with Phase 2 clinical trial for SNS812, a broad-spectrum siRNA for COVID-19 infection, co-developed by Oneness & Microbio (Shanghai)

Oneness Biotech Co., Ltd. Receives Approval from Malaysia NPRA for FESPIXON, the New Drug in Treatment of Diabetic Footulcers

Upcoming dividend of NT$0.098 per share

Oneness Biotech Co., Ltd. Announces Cash Dividend, Payable on July 21, 2023

Full year 2022 earnings: EPS exceeds analyst expectations

Oneness Biotech Co., Ltd., Annual General Meeting, Apr 18, 2023

Third quarter 2022 earnings released

Third quarter 2022 earnings released: EPS: NT$0.71 (vs NT$0.46 loss in 3Q 2021)

Microbio (Shanghai) and Oneness Co-Develop Broad-Spectrum siRNA (SNS812) to Treat SARS-CoV-2 Infection, Greenlighted by FDA to Proceed with A Phase I Study

Oneness Biotech Co., Ltd. Submits an IND to US FDA for A Phase Iclinical Trial on the Broad-Spectrum Anti-SARS-CoV-2siRNA (SNS812) Co-Developed with Microbio (Shanghai)

Second quarter 2022 earnings released: EPS: NT$0.87 (vs NT$1.24 loss in 2Q 2021)

Oneness Biotech Co., Ltd. Announces the By-Election of Lin, Yi-Fu as Director

Oneness Biotech Co., Ltd. Announces the By-Election of Lin, Yi-Fu as Director

First quarter 2022 earnings released: EPS: NT$1.01 (vs NT$0.31 in 1Q 2021)

Oneness Biotech Co., Ltd. Announces Food and Drug Administration Philippines Accepts NDA Application of Diabetic Foot Ulcer New Drug, Fespixon

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Oneness Biotech Co., Ltd. Announces The Malaysia National Pharmaceutical Regulatory Agency Accepts NDA Application of the Diabetic Foot Ulcer New Drug, Fespixon

Oneness Biotech Co., Ltd., Annual General Meeting, May 24, 2022

Oneness Biotech Co., Ltd. Announces the Data of Sns812 Were Published by EMBO Molecular Medicine

Oneness Biotech Co., Ltd. Announces the Partial Efficacy Data for the Phase 2a Study of FB825 in the Treatment of Atopic Dermatitis in the U.S

Third quarter 2021 earnings released: NT$0.46 loss per share (vs NT$0.064 profit in 3Q 2020)

Independent Director Kun-Ta Li has left the company

Second quarter 2021 earnings released: NT$1.24 loss per share (vs NT$1.40 profit in 2Q 2020)

Oneness Biotech Co., Ltd. Announces Phase 3 International MRCT Study Results of the Diabetic Foot Ulcer New Drug

First quarter 2021 earnings released: EPS NT$0.31 (vs NT$0.54 loss in 1Q 2020)

First quarter 2021 earnings released: EPS NT$0.31 (vs NT$0.54 loss in 1Q 2020)

Oneness Notified That FB704A Is Safe to Proceed with the Phase 2 Clinical Trial in Severe Asthma Under US FDA IND

Announcing: Oneness Biotech (GTSM:4743) Stock Soared An Exciting 936% In The Last Three Years

Full year 2020 earnings released: NT$0.68 loss per share (vs NT$1.28 loss in FY 2019)

Oneness Biotech Co., Ltd. Receives the Letter from MOHW Informing that ON101 for DFUs has Obtained the New Drug Approval Andits Drug Certificate Will Be Notified for Receipt

Oneness Biotech Co., Ltd., Annual General Meeting, May 21, 2021

Oneness Submits an IND to US FDA on Phase II Clinical Trial on Severe Asthma of FB704A

Oneness Will Not Proceed with the ON101 Phase3 Clinical Trial (ON101CLCT04) Application with BfArM of Germany Based on Strategic Consideration

New 90-day low: NT$185

New 90-day low: NT$213

TFDA Notifies Oneness of Submitting Supplementary information for Rebuttal of FB704A Phase II Clinical trial Application for Severe Neutrophilic Asthma

New 90-day low: NT$260

Third quarter 2020 earnings released: EPS NT$0.06

New 90-day low: NT$265

CEO Compensation Analysis

CEO

Tenure

Compensation

Board Members

Average Tenure